Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies

Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright

May 7, 2018 8:17 AM EDT

H.C. Wainwright raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $90.00) while maintaining a Buy rating following the company's 1Q. During its 1Q18 corporate update, Sarepta also disclosed an exclusive collaboration and investment in Myonexus Therapeutics.

The alliance,... More

Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company

May 7, 2018 6:20 AM EDT

Needham & Company raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $109.00 (from $75.00) while maintaining a Buy rating.

Analsyt Chad Messer commented, "Sarepta reported in line 1Q:18 Exondys revenues of $64.6M. Exondys received a negative trend vote in the EU, for which Sarepta... More

Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital

May 4, 2018 8:50 AM EDT

RBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $98.00 (from $91.00) while maintaining an Outperform rating.

Analyst Rick Bienkowski commented, "On the back of solid 1Q Exondys 51 sales reaffirming confidence in 2018 revenues and future DMD franchise growth, and increasing enthusiasm into June's... More